Survival and Disease Recurrence in Patients with Duodenal Neuroendocrine Tumours—A Single Centre Cohort

Abstract

Background: Duodenal neuroendocrine tumours (D-NETs) are rare but increasingly diagnosed. This study aimed to assess the overall survival and recurrence rate among patients treated for D-NETs. Methods: Patients with D-NETs were retrospectively reviewed with a median follow-up time of 4.8 years (range 0.0–17.2 years). Results: A total of 32 patients with median age 68.0 years were identified. Fifteen patients underwent surgery while ten patients underwent endoscopic treatment. Mean estimated overall survival for the entire population was 12.1 years (95% CI 9.5–14.7 years), while 5-year overall survival was 81.3%. Tumour grade G1 was associated with longer mean estimated survival compared to G2 tumours (13.2 years versus 4.4 years, p = 0.010). None of the 23 patients who underwent presumed radical endoscopic or surgical resection had disease recurrence during follow-up. Tumours <10 mm could be treated endoscopically whereas a high proportion of patients with tumours 10–20 mm should be considered for surgery. Conclusion: Patients with D-NETs had long overall survival, and mortality was more influenced by other diseases. Both endoscopic and surgical resections were effective as no recurrences were diagnosed during follow-up.

Survival of patients managed in France for duodenal neuroendocrine tumors (D-NET): a 20-year multicenter cohort study from the GTE group: a cohort study

“…First, it is worth noting that the characteristics of our cohort were similar to those reported previously 6 , 7 , 13 – 17 . It was essentially an incidental tumour of grade 1, small size (≤1 cm), bulb or Vater Ampulla location, and stage I TNM.…”

Neuroendocrine Tumor of the Small Intestine in a Patient from the Northern Fluminense Region of the Province of Rio de Janeiro, Brazil

“…The patient under our evaluation conforms to the prevailing pattern observed in neuroendocrine tumor diagnoses of the small intestine, having been identified with a subocclusive intestinal condition induced by mass effect. This alignment underscores the observations made by various authors regarding the latent progression of the condition until generic clinical manifestations emerge, leading to its detection [2,3,8,10,11,15,18,23,24].…”

“…Nevertheless, patients in advanced stages face a considerable risk of recurrence. Timely diagnoses correlate with improved treatment prognoses [2,4,7,9,24,25].…”

Gastroenteropancreatic Neuroendocrine Tumors—Current Status and Advances in Diagnostic Imaging

“…Duodenal NENs account for approximately 2-3% of all GEP-NENs [26]. Tumors can be divided into gastrin-producing tumors, somatostatin-producing tumors, and functional inactive tumors, which are located roughly around the duodenal papilla [27][28][29].…”